Published in Psychopharmacology (Berl) on January 29, 2005
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects (GuaKet) | NCT01600885
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92
Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry (2010) 1.48
Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology (2010) 1.34
Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) (2007) 1.22
Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry (2013) 1.19
Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology (2011) 1.00
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) (2013) 0.93
Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology (Berl) (2006) 0.84
Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims. Psychopharmacology (Berl) (2005) 0.81
Preclinical models of antipsychotic drug action. Int J Neuropsychopharmacol (2013) 0.79
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs (2017) 0.75
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry (1988) 12.39
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
Incentive-sensitization and addiction. Addiction (2001) 4.90
The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1999) 3.78
Ketamine--its pharmacology and therapeutic uses. Anesthesiology (1982) 3.61
The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol (1998) 3.00
Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry (1959) 2.66
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry (2000) 2.26
Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth (1989) 2.11
Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry (1998) 2.02
Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science (1997) 2.01
Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology (1999) 1.97
NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 1.88
The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci (1990) 1.77
Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol (1993) 1.76
Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend (2003) 1.50
Ketamine in chronic pain management: an evidence-based review. Anesth Analg (2003) 1.50
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) (2004) 1.38
A role for sensitization in craving and relapse in cocaine addiction. J Psychopharmacol (1998) 1.37
Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology (1997) 1.34
NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry (1999) 1.26
Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog (1992) 1.21
The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev (2000) 1.20
Illicit use of ketamine in Scotland. J Psychoactive Drugs (1997) 1.18
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) (1999) 1.17
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl) (1998) 1.09
Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand (1997) 1.09
The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology (2000) 1.05
Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res (1991) 0.97
Ketamine dependence. Anaesth Intensive Care (2002) 0.93
Psychobiology of the acute stress response and its relationship to the psychobiology of post-traumatic stress disorder. Psychiatr Clin North Am (2002) 0.87
Effects of repeated treatment with amphetamine or phencyclidine on working memory in the rat. Behav Brain Res (2002) 0.86
Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology (2001) 0.86
Long-term outcome of patients who receive ketamine during research. Biol Psychiatry (2001) 0.86
Phencyclidine-induced behavioral sensitization. Pharmacol Biochem Behav (1994) 0.85
Acute and chronic behavioral interactions between phencyclidine (PCP) and amphetamine: evidence for a dopaminergic role in some PCP-induced behaviors. Pharmacol Biochem Behav (1985) 0.85
Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol Psychiatry (1997) 0.83
Lack of evidence for context-dependent cocaine-induced sensitization in humans: preliminary studies. Pharmacol Biochem Behav (1994) 0.82
m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry (1993) 0.82
The ontogeny of behavioral sensitization to phencyclidine. Neurotoxicol Teratol (1992) 0.80
Animal models of mania. Adv Biochem Psychopharmacol (1995) 0.80
Rating scales in research: the case of negative symptoms. Psychiatry Res (1987) 0.80
Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biol Psychiatry (1999) 0.80
Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther (2001) 0.79
Chronic phenycyclidine (PCP) abuse: a psychiatric perspective--Part II: Psychosis [proceedings]. Psychopharmacol Bull (1980) 0.78
Comparison of the pharmacologic effects of N-allylnormetazocine and phencyclidine: sensitization, cross-sensitization, and opioid antagonist activity. Psychopharmacology (Berl) (1986) 0.75
The anticonvulsant and behavioral effects of phencyclidine and ketamine following chronic treatment in rats. Behav Brain Res (1986) 0.75
Chlorpromazine vs. meperidine in the treatment of phencyclidine psychosis. J Clin Psychiatry (1985) 0.75
The efficacy of ECT in phencyclidine-induced psychosis. J Clin Psychiatry (1984) 0.75
Ketamine tolerance and hallucinations in children. Anaesthesia (1982) 0.75
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry (2004) 6.05
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci U S A (2004) 4.42
Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry (2006) 3.97
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 3.64
Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med (2011) 3.36
Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab (2003) 3.21
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology (2004) 2.87
Test-retest and between-site reliability in a multicenter fMRI study. Hum Brain Mapp (2008) 2.63
Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry (2005) 2.45
A prospective cohort study investigating factors associated with depression during medical internship. Arch Gen Psychiatry (2010) 2.41
The role of default network deactivation in cognition and disease. Trends Cogn Sci (2012) 2.39
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry (2005) 2.36
Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res (2005) 2.35
The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry (2012) 2.34
Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study. Hum Brain Mapp (2009) 2.28
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
Rates of violence in patients classified as high risk by structured risk assessment instruments. Br J Psychiatry (2014) 2.22
Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry (2010) 2.19
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry (2008) 2.17
Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry (2010) 2.16
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med (2012) 2.16
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15
Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry (2005) 2.14
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry (2012) 2.10
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
Prevalence of dissociative disorders in psychiatric outpatients. Am J Psychiatry (2006) 2.04
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry (2002) 2.01
Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci (2006) 1.99
Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry (2002) 1.99
Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry (2004) 1.96
Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci (2003) 1.92
Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2012) 1.91
Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol (2009) 1.90
Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med (2005) 1.89
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res (2007) 1.86
Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. J Magn Reson Imaging (2012) 1.86
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry (2003) 1.81
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res (2011) 1.80
Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry (2003) 1.77
Impairment of working memory maintenance and response in schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry (2008) 1.76
Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry (2011) 1.76
Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol Psychiatry (2005) 1.72
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry (2006) 1.68
Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology (Berl) (2005) 1.67
Impaired visual cortical plasticity in schizophrenia. Biol Psychiatry (2012) 1.67
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. J Clin Psychiatry (2012) 1.67
Rare ADH variant constellations are specific for alcohol dependence. Alcohol Alcohol (2012) 1.66
Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry (2003) 1.64
Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry (2004) 1.64
Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history. Biol Psychiatry (2012) 1.62
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry (2015) 1.62
Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly (2007) 1.62
DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res (2013) 1.60
Genetic and environmental predictors of early alcohol use. Biol Psychiatry (2006) 1.60
Neural correlates of impaired cognitive-behavioral flexibility in anorexia nervosa. Am J Psychiatry (2009) 1.59
Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol (2005) 1.55
Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry (2005) 1.55
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry (2005) 1.52
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry (2005) 1.52
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Glutamate metabolism in major depressive disorder. Am J Psychiatry (2014) 1.52
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry (2005) 1.52
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry (2006) 1.51
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull (2012) 1.50
Genome-wide association study of alcohol dependence implicates KIAA0040 on chromosome 1q. Neuropsychopharmacology (2011) 1.50
Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology (2008) 1.49
Striking differences in glucose and lactate levels between brain extracellular fluid and plasma in conscious human subjects: effects of hyperglycemia and hypoglycemia. J Cereb Blood Flow Metab (2002) 1.48
Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. Biol Psychiatry (2006) 1.47
Preliminary evidence for persistent abnormalities in amygdala volumes in adolescents and young adults with bipolar disorder. Bipolar Disord (2005) 1.47
The neural circuitry mediating shifts in behavioral response and cognitive set in autism. Biol Psychiatry (2007) 1.47
Chest radiograph as a triage tool in the imaging-based diagnosis of pulmonary embolism. AJR Am J Roentgenol (2005) 1.46
Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol (2007) 1.44
Cognitive-behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with binge-eating disorder: a randomized controlled trial. J Consult Clin Psychol (2011) 1.43
Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone. J Psychopharmacol (2010) 1.43
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43